Literature DB >> 33565961

Rapid Spread and Control of Multidrug-Resistant Gram-Negative Bacteria in COVID-19 Patient Care Units.

Ashka Patel, Michele Emerick, Marie K Cabunoc, Michelle H Williams, Michael Anne Preas, Gregory Schrank, Ronald Rabinowitz, Paul Luethy, J Kristie Johnson, Surbhi Leekha.   

Abstract

We describe rapid spread of multidrug-resistant gram-negative bacteria among patients in dedicated coronavirus disease care units in a hospital in Maryland, USA, during May-June 2020. Critical illness, high antibiotic use, double occupancy of single rooms, and modified infection prevention practices were key contributing factors. Surveillance culturing aided in outbreak recognition and control.

Entities:  

Keywords:  COVID-19; MDR; Maryland; SARS-CoV-2; United States; antimicrobial resistance; bacteria; bacterial infections; coronavirus disease; gram-negative; multidrug resistant; outbreak; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

Mesh:

Substances:

Year:  2021        PMID: 33565961      PMCID: PMC8007317          DOI: 10.3201/eid2704.204036

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Bacterial colonization and secondary infection have been described in patients hospitalized with coronavirus disease (COVID-19) (,). We report a single-center experience with spread of multidrug-resistant (MDR) gram-negative bacteria (GNB) in COVID-19 patients in Maryland, USA, during May–June 2020. This investigation was determined to be non–human subjects research by the University of Maryland’s Institutional Review Board. At University of Maryland Medical Center (Baltimore, MD, USA), an 800-bed tertiary-care hospital, since early April 2020, critically ill COVID-19 patients had been housed in 3 dedicated units (), which included 2 intensive care units (ICUs) (units A and B, unit A providing extracorporeal membrane oxygenation support) and 1 intermediate-care unit (unit C). Units were designed as closed, negative-pressure areas where staff remained in the same personal protective equipment while providing care to multiple patients. To accommodate the COVID-19 surge, single-patient ICU rooms in units A and B frequently housed 2 patients. Unit C rooms remained single-occupancy and received patients for step-down care from units A and B. Hospital policy required staff to change gloves and perform hand hygiene (or glove hygiene if wearing 2 layers of gloves) between patients and to wear 2 layers of gowns for patients with resistant organisms and remove the outer gown before moving to the next patient. A team nursing model was used, in which multiple nurses shared responsibilities for each patient during a shift. For routine surveillance, the hospital defined MDR GNB as Enterobacterales, Acinetobacter baumannii, or Pseudomonas aeruginosa nonsusceptible to >2 of piperacillin/tazobactam, cefepime, and a carbapenem. Before COVID-19, we performed admission and weekly surveillance for MDR Enterobacterales and A. baumannii using perirectal swab specimens on medical and surgical ICU patients and monitored hospitalwide MDR GNB incidence by using the first positive clinical or surveillance culture >48 hours postadmission. In mid-May 2020, a cluster of 4 patients with MDR Escherichia coli was identified on unit A. Hospitalwide data showed increase in MDR GNB incidence from baseline (Figure, panel A) (weeks 9–11), driven by E. coli cases on units A and B (Figure, panel B). Further review also revealed several patients with cefepime-resistant E. coli (not meeting institutional MDR criteria), MDR P. aeruginosa, and MDR A. baumannii. Surveillance screens (perirectal swab specimens on all and sputum on ventilated patients) in the 3 units in week 12 identified 18/29 (62%) additional patients with resistant GNB (MDR GNB, cefepime-resistant E. coli, or both). Public health authorities were notified and observations of practice and discussions with leadership were conducted. Twice-weekly surveillance culturing among patients still negative for resistant GNB was instituted (Figure).
Figure

Incidence of patients with a clinical or surveillance culture-positive result indicating MDR or cefepime-resistant Escherichia coli, MDR Acinetobacter baumannii, or MDR Pseudomonas aeruginosa >48 hours after admission to a hospital in Maryland, USA, by week, March 1–July 31, 2020. A) Overall hospitalwide incidence (118 total cases, with 98 positive cultures belonging to outbreak units). Narrow white bars represent the number of surveillance cultures obtained during the outbreak and shaded bars show positive cultures by organism. Arrows show timing of relevant events for transmission and control. B) Incidence of outbreak cases (n = 98) stratified by the 3 units affected by the outbreak. Organisms nonsusceptible to >2 of piperacillin/tazobactam, cefepime, or carbapenem are considered MDR. Patients are included for the first positive culture per organism and therefore might be included more than once. MDR, multidrug-resistant.

Incidence of patients with a clinical or surveillance culture-positive result indicating MDR or cefepime-resistant Escherichia coli, MDR Acinetobacter baumannii, or MDR Pseudomonas aeruginosa >48 hours after admission to a hospital in Maryland, USA, by week, March 1–July 31, 2020. A) Overall hospitalwide incidence (118 total cases, with 98 positive cultures belonging to outbreak units). Narrow white bars represent the number of surveillance cultures obtained during the outbreak and shaded bars show positive cultures by organism. Arrows show timing of relevant events for transmission and control. B) Incidence of outbreak cases (n = 98) stratified by the 3 units affected by the outbreak. Organisms nonsusceptible to >2 of piperacillin/tazobactam, cefepime, or carbapenem are considered MDR. Patients are included for the first positive culture per organism and therefore might be included more than once. MDR, multidrug-resistant. During April 16–July 15, a total of 71 unique patients had positive clinical or surveillance cultures for resistant GNB, including 44 E.coli (33 MDR and 11 cefepime-resistant), 27 MDR P. aeruginosa, and 27 MDR A. baumannii (Appendix Table 1). Twenty-four patients (34%) were co-colonized with >1 resistant GNB. Of the 71 patients, 69 (97%) had received antibiotics before first positive resistant GNB culture, 30 (42%) required extracorporeal membrane oxygenation support, 27 (38%) required renal replacement therapy, 52 (73%) received corticosteroids, 25 (35%) received remdesivir, and 14 (20%) received tocilizumab. Twenty-three (32%) patients ultimately died. Relatedness of early E. coli isolates was assessed by pulsed-field gel electrophoresis (PFGE) (n = 13, weeks 7–11) and genetic β-lactamase determination by Verigene gram-negative blood culture nucleic acid test (Luminex Corporation, https://www.luminexcorp.com) (n = 38, weeks 7–14) (; Appendix). PFGE revealed 3 groups. Groups 1 and 2 (n = 7) were considered related and were negative for β-lactamases; these and 8/10 additional β-lactamase-negative isolates were from unit B. Group 3 (n = 6) isolates did not produce bands but were positive for CTX-M; these and 14/15 additional CTX-M positive isolates (including 10/11 phenotypically cefepime-resistant but not MDR) were from unit A and considered related, suggesting rapid patient-to-patient transmission (Appendix Table 1). MDR P. aeruginosa transmission occurred predominantly in unit A, whereas MDR A. baumannii was largely in unit B. Resistant GNB were likely introduced into unit C from both units A and B (Figure, panel B). Key infection control findings () included tight physical spaces and close proximity of patients in double occupancy (), multiple staff in contact with each patient in the team nursing model, and low compliance with hand and glove hygiene and gown changes between patients. To limit staff exposure to COVID-19 patients, the unit had less support from ancillary services; instead, daily room and equipment cleaning and stocking of medications and supplies were performed by unit-based clinical staff. Outbreak control interventions included discontinuation of double occupancy, frequent infection prevention rounds to promote hand hygiene and glove and gown changes between patients, increased environmental services support, and attention to disinfection of reusable equipment and high-touch surfaces (Appendix Table 2) (). Surveillance culturing showed a decrease in positive cultures over time (Figure). Prolonged critical illness, high antibiotic and corticosteroid use, double occupancy, the team nursing model, and modified infection prevention practice were considered contributors to transmission, underscoring the importance of vigilance to MDR organisms in this setting (,–). Surveillance culturing aided with recognizing the extent of spread and informed early intervention.

Appendix

Additional information about rapid spread and control of multidrug-resistant gram-negative bacteria in COVID-19 patient care units.
  9 in total

Review 1.  Bed occupancy rates and hospital-acquired infections--should beds be kept empty?

Authors:  K Kaier; N T Mutters; U Frank
Journal:  Clin Microbiol Infect       Date:  2012-07-03       Impact factor: 8.067

Review 2.  Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.

Authors:  Timothy M Rawson; Luke S P Moore; Nina Zhu; Nishanthy Ranganathan; Keira Skolimowska; Mark Gilchrist; Giovanni Satta; Graham Cooke; Alison Holmes
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

3.  Evaluation of the nanosphere Verigene BC-GN assay for direct identification of gram-negative bacilli and antibiotic resistance markers from positive blood cultures and potential impact for more-rapid antibiotic interventions.

Authors:  Joseph T Hill; Kim-Dung T Tran; Karen L Barton; Matthew J Labreche; Susan E Sharp
Journal:  J Clin Microbiol       Date:  2014-08-13       Impact factor: 5.948

4.  Multi-drug-resistant infections in the COVID-19 era: a framework for considering the potential impact.

Authors:  D Donà; C Di Chiara; M Sharland
Journal:  J Hosp Infect       Date:  2020-05-17       Impact factor: 3.926

5.  Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge.

Authors:  Priya Nori; Kelsie Cowman; Victor Chen; Rachel Bartash; Wendy Szymczak; Theresa Madaline; Chitra Punjabi Katiyar; Ruchika Jain; Margaret Aldrich; Gregory Weston; Philip Gialanella; Marilou Corpuz; Inessa Gendlina; Yi Guo
Journal:  Infect Control Hosp Epidemiol       Date:  2020-07-24       Impact factor: 3.254

6.  Candida auris Outbreak in a COVID-19 Specialty Care Unit - Florida, July-August 2020.

Authors:  Christopher Prestel; Erica Anderson; Kaitlin Forsberg; Meghan Lyman; Marie A de Perio; David Kuhar; Kendra Edwards; Maria Rivera; Alicia Shugart; Maroya Walters; Nychie Q Dotson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-01-15       Impact factor: 17.586

7.  Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017.

Authors:  Jean-Louis Vincent; Yasser Sakr; Mervyn Singer; Ignacio Martin-Loeches; Flavia R Machado; John C Marshall; Simon Finfer; Paolo Pelosi; Luca Brazzi; Dita Aditianingsih; Jean-François Timsit; Bin Du; Xavier Wittebole; Jan Máca; Santhana Kannan; Luis A Gorordo-Delsol; Jan J De Waele; Yatin Mehta; Marc J M Bonten; Ashish K Khanna; Marin Kollef; Mariesa Human; Derek C Angus
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

8.  COVID-19 and the potential long-term impact on antimicrobial resistance.

Authors:  Timothy M Rawson; Luke S P Moore; Enrique Castro-Sanchez; Esmita Charani; Frances Davies; Giovanni Satta; Matthew J Ellington; Alison H Holmes
Journal:  J Antimicrob Chemother       Date:  2020-07-01       Impact factor: 5.790

9.  Tackling antimicrobial resistance in the COVID-19 pandemic.

Authors:  Haileyesus Getahun; Ingrid Smith; Kavita Trivedi; Sarah Paulin; Hanan H Balkhy
Journal:  Bull World Health Organ       Date:  2020-07-01       Impact factor: 9.408

  9 in total
  22 in total

1.  Bacterial Resistance to Antibiotics and Clonal Spread in COVID-19-Positive Patients on a Tertiary Hospital Intensive Care Unit, Czech Republic.

Authors:  Lenka Doubravská; Miroslava Htoutou Sedláková; Kateřina Fišerová; Vendula Pudová; Karel Urbánek; Jana Petrželová; Magdalena Röderová; Kateřina Langová; Kristýna Mezerová; Pavla Kučová; Karel Axmann; Milan Kolář
Journal:  Antibiotics (Basel)       Date:  2022-06-08

2.  Is the Pendulum of Antimicrobial Drug Resistance Swinging Back after COVID-19?

Authors:  Francesca Serapide; Angela Quirino; Vincenzo Scaglione; Helen Linda Morrone; Federico Longhini; Andrea Bruni; Eugenio Garofalo; Giovanni Matera; Nadia Marascio; Giuseppe Guido Maria Scarlata; Claudia Cicino; Alessandro Russo; Enrico Maria Trecarichi; Carlo Torti
Journal:  Microorganisms       Date:  2022-05-02

3.  Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study).

Authors:  Marco Falcone; Lorenzo Roberto Suardi; Giusy Tiseo; Valentina Galfo; Sara Occhineri; Stefano Verdenelli; Giancarlo Ceccarelli; Melita Poli; Marco Merli; Davide Bavaro; Anna Carretta; Giuseppe Nunnari; Emmanuele Venanzi Rullo; Enrico Maria Trecarichi; Chiara Papalini; Antonina Franco; Rosa Fontana Del Vecchio; Vincenzo Bianco; Rodolfo Punzi; Daniela Francisci; Raffaella Rubino; Carlo Torti; Massimo Puoti; Sergio Carbonara; Antonio Cascio; Annalisa Saracino; Teresa Santantonio; Mario Venditti; Francesco Menichetti
Journal:  JAC Antimicrob Resist       Date:  2022-06-16

4.  Impact of the coronavirus disease 2019 (COVID-19) pandemic on infection control practices in a university hospital.

Authors:  Gabriela Abelenda-Alonso; Mireia Puig-Asensio; Emilio Jiménez-Martínez; Esther García-Lerma; Ana Hornero; Carmen Gutiérrez; Miriam Torrecillas; Cristian Tebé; Miquel Pujol; Jordi Carratalà
Journal:  Infect Control Hosp Epidemiol       Date:  2022-05-20       Impact factor: 6.520

Review 5.  The Complexity of Co-Infections in the Era of COVID-19.

Authors:  Nevio Cimolai
Journal:  SN Compr Clin Med       Date:  2021-04-23

Review 6.  Impact of SARS-CoV-2 Epidemic on Antimicrobial Resistance: A Literature Review.

Authors:  Francesco Vladimiro Segala; Davide Fiore Bavaro; Francesco Di Gennaro; Federica Salvati; Claudia Marotta; Annalisa Saracino; Rita Murri; Massimo Fantoni
Journal:  Viruses       Date:  2021-10-20       Impact factor: 5.048

7.  Interbacterial Transfer of Carbapenem Resistance and Large Antibiotic Resistance Islands by Natural Transformation in Pathogenic Acinetobacter.

Authors:  Elin Svedholm; Samuel Barreto; Xavier Charpentier; Maria-Halima Laaberki; Anne-Sophie Godeux; Anaïs Potron; Samuel Venner
Journal:  mBio       Date:  2022-01-25       Impact factor: 7.786

Review 8.  Implications of COVID-19 Pandemic on the Emergence of Antimicrobial Resistance: Adjusting the Response to Future Outbreaks.

Authors:  Doris Rusic; Marino Vilovic; Josipa Bukic; Dario Leskur; Ana Seselja Perisin; Marko Kumric; Dinko Martinovic; Ana Petric; Darko Modun; Josko Bozic
Journal:  Life (Basel)       Date:  2021-03-10

9.  Multidrug Resistence Prevalence in COVID Area.

Authors:  Caterina Aurilio; Pasquale Sansone; Antonella Paladini; Manlio Barbarisi; Francesco Coppolino; Vincenzo Pota; Maria Caterina Pace
Journal:  Life (Basel)       Date:  2021-06-23

10.  Unveiling the Membrane and Cell Wall Action of Antimicrobial Cyclic Lipopeptides: Modulation of the Spectrum of Activity.

Authors:  Roser Segovia; Judith Solé; Ana Maria Marqués; Yolanda Cajal; Francesc Rabanal
Journal:  Pharmaceutics       Date:  2021-12-17       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.